Oral BMP Complex: A Novel Nutraceutical Approach to Bone and Joint Regeneration

BMP-complex from human bone are known as demineralized bone matrix (DBA used in surgery, in which the hydroxyapatite (mineral) component as well as cells (osteoblast and osteoclast are removed.^7,13,21,22 Cyplexinol® is the first food-sourced BMP complex from bovine cortical leg bone. Cows are grass-fed, organic, and hormone-free.^7,20 This oral complex contains all naturally occurring BMPs. The complex also contains naturally occurring growth factors including transforming growth factor beta (TGF-β), insulin-like growth factor (IGF), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF). This is the first nutraceutical product providing the cellular signals which the body uses to differentiate mesenchymal stem cells (MSC) into osteoblasts and chondrocytes for de novo bone and cartilage tissue.

Therapeutic Applications Using Oral BMP Complex

Osteoporosis

Bone remodeling continues throughout life, with the skeleton being replaced about every 8-10 years. If osteoclastic bone resorption outpaces osteoblastic bone formation, the skeleton is weakened, leading to osteoporosis.⁸ This is common in menopause when estrogen levels decrease. Limited case studies show significant improvement in dual-energy X-ray absorptiometry (DEXA) scans in patients with osteoporosis who used Cyplexinol®. Results showed a range of improvements between 18.5% to 63.63% in 2-5 years, which indicates significant, rapid improvement.²³ One case study showed lumbar spine T-score improvement from -3.8 to -3.3, a 9.3% change, in just 4 months on 450 mg BID.²⁴

Certain populations, such as smokers, may benefit from taking a BMP complex supplement.²³ Smokers have elevated cadmium (Cd) exposure, and Cd inhibits BMP-4 stimulated osteoblast differentiation, predisposing to osteoporosis.²⁵

Osteoarthritis

Several studies have shown rapid benefit with BMP complex for supporting occasional joint pain. A 2023 study showed that Cyplexinol® alleviated self-reported knee and/or hip pain and stiffness. Eighteen men and women were randomly assigned to either twice-daily placebo or Cyplexinol® (900 mg/day) for 14 days. Participants completed pain questionnaires, and blood was analyzed for BMP, alkaline phosphatase, and cytokines. BMP-5 and TGF-β were increased in the Cyplexinol® group. ¹⁵ Though the study was brief, it highlights the potential for fast-acting pain relief. Other studies have found similar outcomes using lower doses for longer times.  These studies are limited but ongoing.

A randomized, prospective, multicenter 2012 trial studied 28 participants with osteoarthritis. The intervention group was given 150 mg Cyplexinol®, 1500 mg glucosamine sulfate, and 1200 mg chondroitin for 4 weeks. There was a significant reduction in overall pain (54.7%) and pain frequency (58.8%) by the end of the trial. Joint strength increased by 33%, and participants were able to increase overall activity.¹³ This study demonstrates the benefit of combining supplements for a favorable outcome.

Two other studies using Cyplexinol® alone showed similar results. A 2013 randomized, double-blind, placebo-controlled trial studied the effect of 150 mg Cyplexinol® or placebo on 87 participants with hip or knee osteoarthritis. Treatment lasted 12 weeks and resulted in a statistically significant improvement in pain, stiffness, and quality of life.²² In an open-label study in 2015, researchers gave 44 participants with osteoarthritis in the hip, knee, and ankle 150 mg Cyplexinol® for 4 weeks. Pain intensity and pain frequency decreased by 45% and 55%, respectively. Strength increased by 80%, and participants were able to increase their activity level.²¹

All studies showed joint comfort improvement beginning as early as the first week and gradually improving each week thereafter.

Safety and Contraindications

Cyplexinol® BMP Complex provides natural physiologic levels of BMPs and growth factors, unlike the elevated concentrations found in synthetic recombinant BMPs used in surgical applications.⁷  No adverse effects were reported by human trial participants taking Cyplexinol®.^15,21,22,26 Synthetic recombinant BMPs are potent and known to have serious side effects.¹

Quality

Cyplexinol® undergoes a rigorous same testing process used by independent orthopedic medical companies by independent laboratories. Every batch is tested in live animals to ensure the product turns on stem cells and grows new tissue, confirmed histologically. This process requires 45-80 days to complete and provides a guarantee that every batch is biologically active, one thing no other supplement offers.^20,21

The Future of Regenerative Health

BMP complex is the only natural growth-factor complex proven to turn on stem cells and grow new bone and cartilage in animal models.^7,26,29-31 Unlike other medications and supplements, which maintain existing tissue, BMP complex naturally initiates true tissue regeneration.

Human studies using Cyplexinol® have demonstrated rapid and lasting benefits, including joint comfort improvement within days, increased bone density in just months, and a significantly improved quality of life. BMP complex also complements other supplements for healthy bone and to alleviate joint pain. Ongoing clinical trials continue to validate its effectiveness and explore promising new applications, including gastrointestinal health.⁷

References

1. Grgurevic L, Pecina M, Vukicevic S. Marshall R. Urist and the discovery of bone morphogenetic proteins. International orthopaedics. 2017;41(5):1065-1069.
2. Carreira AC, Alves GG, Zambuzzi WF, Sogayar MC, Granjeiro JM. Bone Morphogenetic Proteins: structure, biological function and therapeutic applications. Archives of biochemistry and biophysics. 2014;561:64-73.
3. Wu DH, Hatzopoulos AK. Bone morphogenetic protein signaling in inflammation. Experimental biology and medicine (Maywood, NJ). 2019;244(2):147-156.
4. Lee MJ, Yang CW, Jin DC, Chang YS, Bang BK, Kim YS. Bone morphogenetic protein-7 inhibits constitutive and interleukin-1 beta-induced monocyte chemoattractant protein-1 expression in human mesangial cells: role for JNK/AP-1 pathway. Journal of immunology (Baltimore, Md : 1950). 2003;170(5):2557-2563.
5. Gould SE, Day M, Jones SS, Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney international. 2002;61(1):51-60.
6. Beederman M, Lamplot JD, Nan G, et al. BMP signaling in mesenchymal stem cell differentiation and bone formation. Journal of biomedical science and engineering. 2013;6(8a):32-52.
7. Scaffidi J, Vieira K. Cyplexinol: A natural BMP complex with osteoinductive and anti-inflammatory activity promotes De novo bone and joint tissue growth. J Stem Cell Res Ther. 2017;7(387):2.
8. Office of the Surgeon G. Reports of the Surgeon General. In: Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville (MD): Office of the Surgeon General (US); 2004.
9. Merck. Fosamax Package Insert. 2012; https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021575s017lbl.pdf.
10. Stevenson J. Prevention and treatment of osteoporosis in women. Post reproductive health. 2023;29(1):11-14.
11. Kameda T, Mano H, Yuasa T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. The Journal of experimental medicine. 1997;186(4):489-495.
12. Sophia Fox AJ, Bedi A, Rodeo SA. The basic science of articular cartilage: structure, composition, and function. Sports health. 2009;1(6):461-468.
13. Richard Garian D, Scaffidi JJ. An osteoinductive protein complex that stimulates regeneration of bone and cartilage for treatment of moderate to severe osteoarthritis. Integrative Medicine. 2012;11(5):16.
14. Glansbeek HL, van Beuningen HM, Vitters EL, Morris EA, van der Kraan PM, van den Berg WB. Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan synthesis in vivo but does not counteract interleukin-1alpha effects on proteoglycan synthesis and content. Arthritis and rheumatism. 1997;40(6):1020-1028.
15. Pence J, Stockton M, Bloomer RJ. The dietary supplement Cyplexinol(®) alleviates joint pain in men and women. Journal of clinical and translational research. 2023;9(3):212-221.
16. Deng ZH, Li YS, Gao X, Lei GH, Huard J. Bone morphogenetic proteins for articular cartilage regeneration. Osteoarthritis and cartilage. 2018;26(9):1153-1161.
17. Bramlage CP, Häupl T, Kaps C, et al. Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis research & therapy. 2006;8(3):R58.
18. Zhang H, Dang Z, Wang X, Wang C, Zhang H, Zhang Y. BMP9 enhances osteogenic differentiation in rheumatoid arthritis: a potential therapeutic approach. Journal of translational medicine. 2025;23(1):241.
19. Lademann F, Hofbauer LC, Rauner M. The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective. Frontiers in cell and developmental biology. 2020;8:586031.
20. ZyCal Bioceuticals Manufacturing Company. Ostinol Medical Grade Testing 2025; https://ostinol.com/pages/professional-testing.
21. Spinks K, Walker M, Scaffidi J. Clinical Assessment of Low-dose Osteoinductive Protein as a Stand-alone Regimen in Self-reported Osteoarthritis. Integrative medicine (Encinitas, Calif). 2015;14(2):23-32.
22. Richard Garian DC C, Scaffidi JJ. Evaluating clinical response and activity of Cyplexinol osteoinductive proteins in osteoarthritis of the hip and knee: a randomized, controlled trial. Integrative Medicine. 2013;12(2):18.
23. Tripodi D. Osteoinductive Effects of Cyplexinol in the Management of Osteoporosis: A Case Series. Alternative therapies in health and medicine. 2017;23(6):42-47.
24. Wilkinson K, Howard P. Dietary Supplementation With Cyplexinol for Amelioration of Osteoporosis: A Case Study. Alternative therapies in health and medicine. 2019;25(6):44-48.
25. Wan Y, Mo LJ, Wu L, et al. Bone morphogenetic protein 4 is involved in cadmium-associated bone damage. Toxicological sciences : an official journal of the Society of Toxicology. 2023;191(2):201-211.
26. Spinks K, Scaffidi JJ. In Vivo Osteoinduction: Evaluating 2-Beta Coxatene as an Immunoinductive Compound and Novel Ingredient for Joint Support. Integrative medicine (Encinitas, Calif). 2016;15(5):34-44.
27. Urist MR, Hudak RT. Radioimmunoassay of bone morphogenetic protein in serum: a tissue-specific parameter of bone metabolism. Proceedings of the Society for Experimental Biology and Medicine. 1984;176(4):472-475.
28. Colige A, Sieron AL, Li SW, et al. Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. American journal of human genetics. 1999;65(2):308-317.
29. Martínez J, Elorriaga M, Marquínez M, Larralde J. Skeletal growth after oral administration of demineralized bone matrix. Revista Española de Fisiología. 1993;49(1):37-41.
30. Wu M, Wu S, Chen W, Li YP. The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease. Cell research. 2024;34(2):101-123.
31. Simic P, Culej JB, Orlic I, et al. Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption. The Journal of biological chemistry. 2006;281(35):25509-25521.